Emergent BioSolutions | EBS - Ativo Circulante





Ativo Circulante Alterar Data
Acadia Pharmaceuticals USD 1.1B 33.9M 2026-03
Akebia Therapeutics USD 243.48M 9.47M 2026-03
ALKERMES USD 1.36B 570.52M 2026-03
Alnylam Pharmaceuticals USD 4.22B 168.65M 2026-03
Amarin USD 626.02M 23.87M 2026-03
ANI Pharmaceuticals USD 747.08M 6.03M 2026-03
BioMarin Pharmaceutical USD 4.61B 651.58M 2026-03
Coherus Biosciences USD 206.71M 254.25M 2025-12
Emergent BioSolutions USD 679.5M 41.3M 2023-12
Exelixis USD 1.21B 234.65M 2026-03
Glaxosmithkline GBP 23.59B 390.44M 2025-12
Heron Therapeutics USD 228.98M 9.08M 2026-03
Ionis Pharmaceuticals USD 2.94B 52M 2026-03
Ironwood Pharmaceuticals USD 332.29M 58.11M 2026-03
Lexicon Pharmaceuticals USD 186.03M 84.14M 2026-03
Lonza CHF 8B 3.41B 2025-12
Merck USD 35.02B 8.5B 2026-03
Moderna USD 5.77B 774M 2026-03
Myriad Genetics USD 312.8M 19.8M 2026-03
Nektar Therapeutics USD 266.27M 15.09M 2025-12
Neurocrine Biosciences USD 2.44B 86.6M 2026-03
Pacira USD 514.96M 33.01M 2026-03
Pfizer USD 42.82B 76M 2026-03
PTC Therapeutics USD 2.25B 19.94M 2026-03
Sanofi EUR 30.16B 789M 2026-03
Sarepta Therapeutics USD 2.31B 228.06M 2026-03
United Therapeutics USD 2.87B 830.5M 2026-03
Vanda Pharmaceuticals USD 347.26M 20.23M 2025-12
Xoma USD 110.71M 5.78M 2025-09